OncoMatch

OncoMatch/Clinical Trials/NCT04437329

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

Is NCT04437329 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Docetaxel, nedaplatin, fluorouracil and Docetaxel, cisplatin, fluorouracil for nasopharyngeal carcinoma.

Phase 3RecruitingAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityNCT04437329Data as of Jun 2026Location: China

Treatment: Docetaxel, nedaplatin, fluorouracil · Docetaxel, cisplatin, fluorouracil · Nedaplatin · CisplatinTo compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

Docetaxel, nedaplatin, fluorouracilDocetaxel, cisplatin, fluorouracilNedaplatinCisplatin

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage III, IVA

Excluded: Stage T3-4N0

Performance status

KARNOFSKY 70–100

KARNOFSKY scale (KPS) > 70

Demographics

Ages ≤ 65

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: radiotherapy

Exception: diagnostic surgery allowed

History of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to the primary tumor or nodes

Cannot have received: chemotherapy

Exception: diagnostic surgery allowed

History of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to the primary tumor or nodes

Cannot have received: surgery

Exception: diagnostic surgery allowed

History of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to the primary tumor or nodes

Lab requirements

Blood counts

WBC ≥ 4×10^9/l, platelet ≥ 100×10^9/l, hemoglobin ≥ 90g/l

Kidney function

creatinine ≤ 1.5×uln or ccr ≥ 60ml/min

Liver function

TBIL, ALT, AST ≤ 2.5×uln

WBC≥4×10^9/ l, platelet ≥ 100×10^9/ l and hemoglobin ≥ 90g/l; normal liver function test (TBIL、ALT、AST ≤ 2.5×uln); normal renal function test (creatinine ≤ 1.5×uln or ccr ≥ 60ml/min)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04437329 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage III or IVA is required.

Is there an age limit?

Yes. Patients must be 65 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify